Literature DB >> 17705947

Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk.

R Panjabi1, G W Comstock, J E Golub.   

Abstract

Recurrent tuberculosis (TB) poses significant threats, including drug resistance, to TB control programs. However, recurrence and its causes, particularly in the era of epidemic human immunodeficiency virus (HIV), have not been well described. We systematically searched published material for studies reporting on recurrent TB following completion of standard treatment regimens to provide data on the issue. A total of 32 studies were reviewed. Among controlled trials, the overall recurrence rates (per 100,000 person-years) were respectively 3,010 (95%CI 2,230-3,970) and 2,290 (95%CI 1,730-2,940) at 6 and 12 months after treatment completion. Recurrence rates were higher among observational studies compared to controlled trials and in countries with high versus low background TB incidence. TB recurrence (%) was higher among HIV-infected (6.7, 95%CI 5.9-7.6) than non-HIV-infected individuals (3.3, 95%CI 2.8-3.9). Factors independently associated with recurrence in the literature included residual cavitation, greater area of involved lung tissue, positive sputum culture at 2 months of treatment and HIV infection. Among those with HIV infection, recurrent TB was associated with a low initial CD(4) count and receiving less than 37 weeks of anti-tuberculosis treatment. We argue that adequately treated patients are still at high risk for recurrent disease and should be considered in case-finding strategies. Moreover, those with multiple risk factors may benefit from modification of standard treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17705947

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  50 in total

1.  An adjunctive therapeutic vaccine against reactivation and post-treatment relapse tuberculosis.

Authors:  Toshiko Miyata; Chan-Ick Cheigh; Nicola Casali; Amador Goodridge; Olivera Marjanovic; Lon V Kendall; Lee W Riley
Journal:  Vaccine       Date:  2011-11-08       Impact factor: 3.641

2.  How host heterogeneity governs tuberculosis reinfection?

Authors:  M Gabriela M Gomes; Ricardo Aguas; João S Lopes; Marta C Nunes; Carlota Rebelo; Paula Rodrigues; Claudio J Struchiner
Journal:  Proc Biol Sci       Date:  2012-02-22       Impact factor: 5.349

3.  Characteristics of adults and children diagnosed with tuberculosis in Lilongwe, Malawi: findings from an integrated HIV/TB clinic.

Authors:  C Feldacker; H Tweya; O Keiser; R Weigel; M Kalulu; L Fenner; M Egger; E Manda; J B Mwafilaso; C Kamba; S Phiri
Journal:  Trop Med Int Health       Date:  2012-07-19       Impact factor: 2.622

4.  In vitro and in vivo fitness costs associated with Mycobacterium tuberculosis RpoB mutation H526D.

Authors:  Dalin Rifat; Victoria L Campodónico; Jing Tao; James A Miller; Alpaslan Alp; Yufeng Yao; Petros C Karakousis
Journal:  Future Microbiol       Date:  2017-03-27       Impact factor: 3.165

5.  Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis.

Authors:  Florian M Marx; Ted Cohen; Nicolas A Menzies; Joshua A Salomon; Grant Theron; Reza Yaesoubi
Journal:  Lancet Glob Health       Date:  2020-09       Impact factor: 26.763

Review 6.  Immunometabolism within the tuberculosis granuloma: amino acids, hypoxia, and cellular respiration.

Authors:  Joseph E Qualls; Peter J Murray
Journal:  Semin Immunopathol       Date:  2015-10-21       Impact factor: 9.623

7.  Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa.

Authors:  Helen S Cox; Cheryl McDermid; Virginia Azevedo; Odelia Muller; David Coetzee; John Simpson; Marinus Barnard; Gerrit Coetzee; Gilles van Cutsem; Eric Goemaere
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

8.  Exogenous Reinfection as a Cause of Late Recurrent Tuberculosis in the United States.

Authors:  Julia D Interrante; Maryam B Haddad; Lindsay Kim; Neel R Gandhi
Journal:  Ann Am Thorac Soc       Date:  2015-11

Review 9.  Epidemiology of HIV-associated tuberculosis.

Authors:  Stephen D Lawn; Gavin Churchyard
Journal:  Curr Opin HIV AIDS       Date:  2009-07       Impact factor: 4.283

Review 10.  Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings.

Authors:  Stephen D Lawn; Katharina Kranzer; Robin Wood
Journal:  Clin Chest Med       Date:  2009-12       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.